PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
BFLY vs. ACRS
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between BFLY and ACRS is 0.31, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

BFLY vs. ACRS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Butterfly Network, Inc. (BFLY) and Aclaris Therapeutics, Inc. (ACRS). The values are adjusted to include any dividend payments, if applicable.

0.00%50.00%100.00%150.00%200.00%250.00%AugustSeptemberOctoberNovemberDecember2025
249.16%
85.71%
BFLY
ACRS

Key characteristics

Sharpe Ratio

BFLY:

2.60

ACRS:

1.20

Sortino Ratio

BFLY:

3.26

ACRS:

2.67

Omega Ratio

BFLY:

1.36

ACRS:

1.34

Calmar Ratio

BFLY:

2.76

ACRS:

1.24

Martin Ratio

BFLY:

10.54

ACRS:

6.12

Ulcer Index

BFLY:

25.50%

ACRS:

19.65%

Daily Std Dev

BFLY:

103.58%

ACRS:

100.50%

Max Drawdown

BFLY:

-97.40%

ACRS:

-98.05%

Current Drawdown

BFLY:

-85.59%

ACRS:

-92.12%

Fundamentals

Market Cap

BFLY:

$833.07M

ACRS:

$278.25M

EPS

BFLY:

-$0.47

ACRS:

-$0.52

Total Revenue (TTM)

BFLY:

$59.70M

ACRS:

$9.51M

Gross Profit (TTM)

BFLY:

$35.10M

ACRS:

$3.35M

EBITDA (TTM)

BFLY:

-$45.55M

ACRS:

-$38.09M

Returns By Period

In the year-to-date period, BFLY achieves a 25.32% return, which is significantly higher than ACRS's 4.84% return.


BFLY

YTD

25.32%

1M

26.54%

6M

249.11%

1Y

258.72%

5Y*

N/A

10Y*

N/A

ACRS

YTD

4.84%

1M

-4.41%

6M

85.71%

1Y

106.35%

5Y*

10.24%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

BFLY vs. ACRS — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BFLY
The Risk-Adjusted Performance Rank of BFLY is 9393
Overall Rank
The Sharpe Ratio Rank of BFLY is 9696
Sharpe Ratio Rank
The Sortino Ratio Rank of BFLY is 9393
Sortino Ratio Rank
The Omega Ratio Rank of BFLY is 8888
Omega Ratio Rank
The Calmar Ratio Rank of BFLY is 9494
Calmar Ratio Rank
The Martin Ratio Rank of BFLY is 9292
Martin Ratio Rank

ACRS
The Risk-Adjusted Performance Rank of ACRS is 8585
Overall Rank
The Sharpe Ratio Rank of ACRS is 8282
Sharpe Ratio Rank
The Sortino Ratio Rank of ACRS is 8888
Sortino Ratio Rank
The Omega Ratio Rank of ACRS is 8787
Omega Ratio Rank
The Calmar Ratio Rank of ACRS is 8383
Calmar Ratio Rank
The Martin Ratio Rank of ACRS is 8484
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

BFLY vs. ACRS - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Butterfly Network, Inc. (BFLY) and Aclaris Therapeutics, Inc. (ACRS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for BFLY, currently valued at 2.60, compared to the broader market-2.000.002.004.002.601.20
The chart of Sortino ratio for BFLY, currently valued at 3.26, compared to the broader market-4.00-2.000.002.004.006.003.262.67
The chart of Omega ratio for BFLY, currently valued at 1.36, compared to the broader market0.501.001.502.001.361.34
The chart of Calmar ratio for BFLY, currently valued at 2.76, compared to the broader market0.002.004.006.002.761.25
The chart of Martin ratio for BFLY, currently valued at 10.54, compared to the broader market0.0010.0020.0030.0010.546.12
BFLY
ACRS

The current BFLY Sharpe Ratio is 2.60, which is higher than the ACRS Sharpe Ratio of 1.20. The chart below compares the historical Sharpe Ratios of BFLY and ACRS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.00AugustSeptemberOctoberNovemberDecember2025
2.60
1.20
BFLY
ACRS

Dividends

BFLY vs. ACRS - Dividend Comparison

Neither BFLY nor ACRS has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

BFLY vs. ACRS - Drawdown Comparison

The maximum BFLY drawdown since its inception was -97.40%, roughly equal to the maximum ACRS drawdown of -98.05%. Use the drawdown chart below to compare losses from any high point for BFLY and ACRS. For additional features, visit the drawdowns tool.


-96.00%-94.00%-92.00%-90.00%-88.00%-86.00%-84.00%AugustSeptemberOctoberNovemberDecember2025
-85.59%
-91.22%
BFLY
ACRS

Volatility

BFLY vs. ACRS - Volatility Comparison

Butterfly Network, Inc. (BFLY) has a higher volatility of 38.93% compared to Aclaris Therapeutics, Inc. (ACRS) at 18.84%. This indicates that BFLY's price experiences larger fluctuations and is considered to be riskier than ACRS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%60.00%70.00%AugustSeptemberOctoberNovemberDecember2025
38.93%
18.84%
BFLY
ACRS

Financials

BFLY vs. ACRS - Financials Comparison

This section allows you to compare key financial metrics between Butterfly Network, Inc. and Aclaris Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab